A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.

Simple item page
dc.contributor.authorArj-ong, Sakdaen_US
dc.contributor.authorChotivitayatarakorn, Pairojen_US
dc.contributor.authorLertsapcharoen, Pornthepen_US
dc.contributor.authorKhongphatthanayothin, Apichaien_US
dc.contributor.authorThisyakorn, Chuleen_US
dc.date.accessioned2009-05-27T20:41:21Z
dc.date.available2009-05-27T20:41:21Z
dc.date.issued2003-06-22en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractTo determine the long-term cost-benefit of intravenous immunoglobulin (IVIG) treatment in Children with Kawasaki Disease (KD), a model was made to compare the total cost for management of these children with and without the use of IVIG. Long-term (10-21 years) follow-up of 594 KD patients treated in the pre-IVIG era reported by Kato, et al. was used to calculate cost using previous cost studies from Chulalongkorn Hospital. Reduction of CAA from 25 per cent to 4 per cent with IVIG treatment was assumed based on previous published data. Total cost was slightly lower for the non-IVIG treatment group compared to the IVIG treatment group (33,451,129 baht vs 35,001,195 baht) for the duration of follow-up in Kato's model. Cost per effectiveness analysis showed more effectiveness in the IVIG treatment group (359,576 baht vs 383,614 baht). Net cost analysis similarly demonstrated lower costs in the IVIG treatment group (25,365,215 baht vs 33,451,129 baht). Incremental cost-effectiveness analysis demonstrated supplementary costs of 13,663 baht for one case in the reduction of coronary involvement and 387,517 baht for one life saved in the IVIG-treated group. Estimation of total costs for follow-up and treatment for healthy life (until 60 years old) was more expensive in the non-IVIG treatment than the IVIG treated group (75,482,803 baht vs 29,883,833 baht). The authors conclude that treatment of all KD cases in Thailand with IVIG is likely to result in lower cost and better outcome when compared to no treatment with the IVIG policy.en_US
dc.description.affiliationDivision of Cardiology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.en_US
dc.identifier.citationArj-ong S, Chotivitayatarakorn P, Lertsapcharoen P, Khongphatthanayothin A, Thisyakorn C. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease. Journal of the Medical Association of Thailand. 2003 Jun; 86 Suppl 2(): S179-88en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/43457
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshCost-Benefit Analysisen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoglobulins, Intravenous --economicsen_US
dc.subject.meshInfanten_US
dc.subject.meshMucocutaneous Lymph Node Syndrome --drug therapyen_US
dc.subject.meshTime Factorsen_US
dc.titleA cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand